Medpace Holdings, Inc.
513.579.9911 x 12523
Medpace Celebrates 25 Years as a Clinical Research Organization Focused on Accelerating the Global Development of Safe and Effective Medical Therapeutics
CINCINNATI, Ohio, June 15, 2017 – Next month, Medpace (Nasdaq: MEDP) marks its 25th year as a scientifically-driven, global full-service clinical research organization (CRO). Founded in July, 1992 by Dr. August J. Troendle, Medpace has grown from a small group of dedicated people looking for a better way to conduct clinical research to a publically-held, global community of 2,500 employees across 35 countries.
Challenged the status quo for CROs and created a new model – Physician-led clinical development
Dr. August Troendle, a noted medical doctor and scientist in the study of lipid-altering agents, saw an opportunity in 1992 to offer a more innovative way to conduct clinical trials on behalf of biopharmaceutical sponsors. His vision for a physician-led, full-service CRO with expertise in specific therapeutic areas led to the founding of Medpace. The company capitalized on an unmet need in the life science sector with a model that delivers a much higher level of outsourcing that combines the expertise of noted industry medical doctors with regulatory and operational professionals who provide therapeutic and regulatory expertise for the most difficult clinical studies.
Today, Medpace supports global clinical research from its 30 offices around the world as well as its fully integrated and wholly-owned subsidiaries including central labs, bioanalytical lab, phase I unit for first-in-man studies, imaging core lab, and cardiovascular core lab.
Reputation for Quality
Over the years, Medpace has earned a reputation for quality. Most recently, Industry Standard Report’s “CRO Quality Benchmarking – Phase II/III Service Providers (9th Edition), April, 2017” recognized Medpace as a top performer in numerous categories including customer loyalty, organizational characteristics (breadth of services, financial strength/stability, global footprint, operational excellence), and staff characteristics (CRA quality, project manager quality, project team chemistry, responsiveness, staff turnover, study design expertise, therapeutic expertise, timely project communications). Based on these results, Medpace was also named a “2017 CRO Leadership Award” recipient by Life Science Leader.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries.